Nearly 40 million Americans say they have trouble hearing for one reason or another. There are no drug treatments, just hearing aids and cochlear implants, but biotech companies such as Frequency Therapeutics and Decibel Therapeutics believe they now have the means to make noise in this largely untapped market.
The race to drug the ears, so to speak, might soon include gene editing tools. In a paper published today in the journal Nature, scientific founders of Decibel and Editas Medicine (NASDAQ: EDIT), a leading CRISPR-Cas9 drug firm, and other authors show how they used the CRISPR-Cas9 gene editing system… Read more »
UNDERWRITERS AND PARTNERS